FARMERS & MERCHANTS TRUST Co OF LONG BEACH increased its position in shares of Pfizer Inc. (NYSE:PFE) by 6.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 48,598 shares of the biopharmaceutical company’s stock after purchasing an additional 2,975 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Pfizer were worth $1,761,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Kinloch Capital LLC acquired a new stake in Pfizer during the fourth quarter worth about $25,000. Alpha DNA Investment Management LLC acquired a new stake in shares of Pfizer during the fourth quarter valued at about $26,000. Penbrook Management LLC acquired a new stake in shares of Pfizer during the fourth quarter valued at about $27,000. Orion Capital Management LLC acquired a new stake in shares of Pfizer during the fourth quarter valued at about $29,000. Finally, Merrion Investment Management Co LLC acquired a new stake in shares of Pfizer during the fourth quarter valued at about $30,000. Hedge funds and other institutional investors own 67.36% of the company’s stock.
Pfizer stock traded up $0.05 during trading on Monday, reaching $36.65. The stock had a trading volume of 358,950 shares, compared to its average volume of 31,853,941. Pfizer Inc. has a 52-week low of $31.61 and a 52-week high of $43.08. The business has a 50 day moving average price of $35.11 and a 200 day moving average price of $36.57. The company has a quick ratio of 1.13, a current ratio of 1.40 and a debt-to-equity ratio of 0.76. The stock has a market cap of $204.42 billion, a PE ratio of 23.52, a P/E/G ratio of 2.79 and a beta of 0.70.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The firm had revenue of $11.68 billion during the quarter, compared to analysts’ expectations of $11.32 billion. During the same quarter in the prior year, the firm earned $0.55 EPS. The firm’s revenue was up 11.8% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 2.89 EPS for the current fiscal year.
A number of brokerages have weighed in on PFE. The Goldman Sachs Group set a $41.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research report on Tuesday, April 6th. Mizuho dropped their price target on shares of Pfizer from $44.00 to $42.00 and set a “buy” rating for the company in a research report on Wednesday, February 3rd. JPMorgan Chase & Co. set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research report on Wednesday, February 3rd. TheStreet lowered shares of Pfizer from a “b” rating to a “c+” rating in a research note on Friday, March 5th. Finally, Royal Bank of Canada initiated coverage on shares of Pfizer in a research note on Wednesday, April 7th. They issued a “sector perform” rating and a $42.00 price objective for the company. Eleven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $38.47.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).